Robert W. Baird Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective dropped by Robert W. Baird from $759.00 to $652.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a "neutral" rating on the biopharmaceutical company's stock. Robert W. Baird's price target would suggest a potential upside of 10.79% from the stock's previous close.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company cut their price target on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a report on Friday, January 10th. TD Cowen lowered their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating on the stock in a research report on Tuesday, February 4th. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Citigroup lowered their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 28th. Finally, Truist Financial lowered their price objective on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $918.12.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $19.57 on Friday, reaching $588.48. The company had a trading volume of 609,370 shares, compared to its average volume of 735,406. The stock has a market capitalization of $64.34 billion, a PE ratio of 15.37, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a one year low of $525.99 and a one year high of $1,211.20. The business's 50-day moving average is $633.34 and its 200 day moving average is $718.04.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period in the previous year, the business posted $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. Equities research analysts forecast that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pamalican Asset Management Ltd purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $4,915,000. Intact Investment Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $356,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the 4th quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company's stock worth $30,956,000 after buying an additional 4,457 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 3rd quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company's stock worth $181,961,000 after buying an additional 2,828 shares during the last quarter. Finally, Fagan Associates Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 42.2% in the 4th quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company's stock worth $9,205,000 after buying an additional 3,832 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.